PE20030385A1 - Compuestos de urea como antagonistas de receptores y5 del neuropeptido y - Google Patents
Compuestos de urea como antagonistas de receptores y5 del neuropeptido yInfo
- Publication number
- PE20030385A1 PE20030385A1 PE2002000653A PE2002000653A PE20030385A1 PE 20030385 A1 PE20030385 A1 PE 20030385A1 PE 2002000653 A PE2002000653 A PE 2002000653A PE 2002000653 A PE2002000653 A PE 2002000653A PE 20030385 A1 PE20030385 A1 PE 20030385A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- cycloalkyl
- alcoxy
- hydroxy
- aryl
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 102000028582 Neuropeptide Y5 receptor Human genes 0.000 title abstract 2
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 title abstract 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical class NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 5
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000000578 anorexic effect Effects 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 229940125710 antiobesity agent Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000003749 thyromimetic agent Substances 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
SE REFIERE A DERIVADOS DE UREA DE FORMULA I DONDE X ES N, C; Z ES NR8, CR3R9; D ES H, OH, ALQUILO, CUANDO X ES N, D, ENLACE X-D ESTA AUSENTE; E ES H, ALQUILO; D Y E ESTAN UNIDOS A TRAVES DE UN PUENTE (CH2)p; Q ES H, ALQUILO, D, X, Q FORMAN UN ANILLO DE 3-7 MIEMBROS; g, j, m, n SON 0-3, j+k ES 0-3; m+n ES 1-5; p ES 1-3; R1 ES H, OH, HALOGENO, HALOALQUILO, CICLOALQUILO, CN, ALCOXI, CICLOALCOXI, NR5R6, NO2, CONR5R6, ENTRE OTROS; R2 ES H, ALQUILO, ALCOXI, HIDROXI; CUANDO X ES N; R2 ES HIDROXI, ALCOXI; R2 NO ESTA DIRECTAMENTE UNIDO A X; R3 ES H, ALQUILO; R4 ES H, ALQUILO, ALCOXI, HIDROXI, CUANDO Z ES NR8, R4 ES HIDROXI, ALCOXI; R4 NO ESTA ADHERIDO A UN CARBONO ADYACENTE A NR8; R5 Y R6 SON H, ALQUILO, CICLOALQUILO; R7 ES ALQUILO, CICLOALQUILO; R8 ES H, ALQUILO, CICLOALQUILO, ALQUILCICLOALQUILO, ARILO, ENTRE OTROS; R9 ES H, ALQUILO, HIDROXI, ALCOXI, NR5R11; R3 Y R9 SON FORMAN UN CARBOCICLO, HETEROCICLO DE 3-7 MIEMBROS; R10 ES ALQUILO, CICLOALQUILO, ALQUILCICLOALQUILO, ARILO, HETAROARILO; R11 ES H, ALQUILO, CICLOALQUILO, ARILO, HETEOARILO. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN AGENTE ANTIOBESIDAD, ANOREXICO, AGENTE TIROMIMETICO, ANOREXIGENO, ANTAGONISTAS NPY. LOS COMPUESTOS SON ANTAGONISTADEL RECEPTOR Y5 DEL NEUROPEPTIDO NPY Y PUEDE SER UTIL PARA EL TRATAMIENTO DE DESORDEN METABOLICO, DESORDEN DE ALIMENTACION (OBESIDAD, HIPERFAGIA), DIABETES, RESISTENCIA A INSULINA, HIPERLIPIDEMIA, HIPERTENSION
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30843301P | 2001-07-26 | 2001-07-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030385A1 true PE20030385A1 (es) | 2003-05-08 |
Family
ID=23193972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002000653A PE20030385A1 (es) | 2001-07-26 | 2002-07-24 | Compuestos de urea como antagonistas de receptores y5 del neuropeptido y |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6667319B2 (es) |
| EP (1) | EP1418913A1 (es) |
| JP (1) | JP2005500338A (es) |
| CN (2) | CN1558764A (es) |
| AR (1) | AR036191A1 (es) |
| AU (1) | AU2002355286B2 (es) |
| CA (1) | CA2454830C (es) |
| HU (1) | HUP0401643A3 (es) |
| IL (1) | IL159643A0 (es) |
| IS (1) | IS7096A (es) |
| MX (1) | MXPA04000707A (es) |
| NZ (1) | NZ530429A (es) |
| PE (1) | PE20030385A1 (es) |
| PL (1) | PL368201A1 (es) |
| TW (1) | TWI300064B (es) |
| WO (1) | WO2003009845A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| IL160983A0 (en) * | 2001-09-24 | 2004-08-31 | Imp College Innovations Ltd | Use of pyy for preparation of a medicament for modification of feeding behavior |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2520763A1 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| US20090018092A1 (en) | 2004-03-16 | 2009-01-15 | The Regents Of The University Of California | Reducing Nephropathy with Inhibitors of Soluble Epoxide Hydrolase and Epoxyeicosanoids |
| WO2005097127A2 (en) | 2004-04-02 | 2005-10-20 | Merck & Co., Inc. | Method of treating men with metabolic and anthropometric disorders |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| JP2008517072A (ja) | 2004-10-20 | 2008-05-22 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 可溶性エポキシド加水分解酵素の改良された阻害剤 |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| KR20080025190A (ko) * | 2005-06-30 | 2008-03-19 | 프로시디온 리미티드 | Ｇ-단백질 결합된 수용체 효능제 |
| FR2894964B1 (fr) * | 2005-12-19 | 2008-02-22 | Cerep Sa | Composes a base de quatre cycles aromatiques, preparation et utilisations |
| TW200808723A (en) | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| TW200815353A (en) | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| EP2058305A4 (en) | 2006-08-30 | 2010-09-22 | Shionogi & Co | UREA DERIVATIVE |
| TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2009040659A2 (en) | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2012054093A2 (en) | 2010-01-29 | 2012-04-26 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| JP2013520502A (ja) | 2010-02-25 | 2013-06-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体 |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| JP5728099B2 (ja) | 2011-02-25 | 2015-06-03 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 抗糖尿病剤として有用な新規環状アザベンゾイミダゾール誘導体 |
| CN102675190A (zh) * | 2012-05-23 | 2012-09-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种3-（二甲氨基）次甲基-n-甲磺酰基哌啶-4-酮的合成方法 |
| CA2880901A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| RU2015140066A (ru) | 2013-02-22 | 2017-03-30 | Мерк Шарп И Доум Корп. | Противодиабетические бициклические соединения |
| EP2970119B1 (en) | 2013-03-14 | 2021-11-03 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
| JP2016514671A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼのアゴニストおよびその使用 |
| JP2016514670A (ja) | 2013-03-15 | 2016-05-23 | シナジー ファーマシューティカルズ インコーポレイテッド | 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト |
| ES2981866T3 (es) | 2013-06-05 | 2024-10-10 | Bausch Health Ireland Ltd | Agonistas ultrapuros de guanilato ciclasa C, método de elaboración y uso de los mismos |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| US11072602B2 (en) | 2016-12-06 | 2021-07-27 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| AU2019207887B2 (en) | 2018-01-11 | 2024-05-23 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| WO2022076365A1 (en) * | 2020-10-06 | 2022-04-14 | Eastman Chemical Company | Aromatic enol ethers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
| US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| ATE232200T1 (de) | 1998-06-08 | 2003-02-15 | Schering Corp | Neuropeptid y5-rezeptorantagonisten |
| CA2350714A1 (en) | 1998-11-10 | 2000-05-18 | Merck & Co., Inc. | Spiro-indolines as y5 receptor antagonists |
| US20020165223A1 (en) * | 2000-09-14 | 2002-11-07 | Greenlee William J. | Substituted urea neuropeptide Y Y5 receptor antagonists |
-
2002
- 2002-07-24 HU HU0401643A patent/HUP0401643A3/hu unknown
- 2002-07-24 CA CA002454830A patent/CA2454830C/en not_active Expired - Fee Related
- 2002-07-24 WO PCT/US2002/023552 patent/WO2003009845A1/en active IP Right Grant
- 2002-07-24 PE PE2002000653A patent/PE20030385A1/es not_active Application Discontinuation
- 2002-07-24 IL IL15964302A patent/IL159643A0/xx unknown
- 2002-07-24 EP EP02752562A patent/EP1418913A1/en not_active Withdrawn
- 2002-07-24 AR ARP020102785A patent/AR036191A1/es unknown
- 2002-07-24 TW TW091116480A patent/TWI300064B/zh active
- 2002-07-24 US US10/202,239 patent/US6667319B2/en not_active Expired - Fee Related
- 2002-07-24 AU AU2002355286A patent/AU2002355286B2/en not_active Ceased
- 2002-07-24 JP JP2003515237A patent/JP2005500338A/ja active Pending
- 2002-07-24 NZ NZ530429A patent/NZ530429A/en unknown
- 2002-07-24 CN CNA028189647A patent/CN1558764A/zh active Pending
- 2002-07-24 MX MXPA04000707A patent/MXPA04000707A/es active IP Right Grant
- 2002-07-24 CN CNA2006101215468A patent/CN1911913A/zh active Pending
- 2002-07-24 PL PL02368201A patent/PL368201A1/xx not_active Application Discontinuation
-
2003
- 2003-10-24 US US10/692,559 patent/US7304076B2/en not_active Expired - Fee Related
- 2003-12-31 IS IS7096A patent/IS7096A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2454830A1 (en) | 2003-02-06 |
| TWI300064B (en) | 2008-08-21 |
| CN1911913A (zh) | 2007-02-14 |
| IS7096A (is) | 2003-12-31 |
| NZ530429A (en) | 2005-09-30 |
| CN1558764A (zh) | 2004-12-29 |
| HUP0401643A2 (hu) | 2004-12-28 |
| US20040102474A1 (en) | 2004-05-27 |
| CA2454830C (en) | 2010-02-02 |
| AU2002355286B2 (en) | 2005-10-13 |
| WO2003009845A1 (en) | 2003-02-06 |
| EP1418913A1 (en) | 2004-05-19 |
| IL159643A0 (en) | 2004-06-01 |
| JP2005500338A (ja) | 2005-01-06 |
| US20030207860A1 (en) | 2003-11-06 |
| US6667319B2 (en) | 2003-12-23 |
| HUP0401643A3 (en) | 2009-06-29 |
| AR036191A1 (es) | 2004-08-18 |
| WO2003009845A9 (en) | 2004-03-11 |
| PL368201A1 (en) | 2005-03-21 |
| MXPA04000707A (es) | 2004-04-20 |
| US7304076B2 (en) | 2007-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030385A1 (es) | Compuestos de urea como antagonistas de receptores y5 del neuropeptido y | |
| CY1119814T1 (el) | Νεες ενωσεις που εχουν ανασταλτικη δραστικοτητα εναντια στον εξαρτωμενο απο το νατριο μεταφορεα γλυκοζης | |
| CL2004000860A1 (es) | Compuesto biciclico de pirazol o imidazol de formula definida, como ligando del receptor cannabinoide que actua como antagonista del receptor cb1; composicion farmaceutica que comprende al compuesto y uso del compuesto en la preparacion de un medicam | |
| EA200301215A1 (ru) | Лиганды рецепторов 5-ht и их применение | |
| PE20061377A1 (es) | Compuestos heterociclicos fusionados | |
| CO5031253A1 (es) | Antagonistas receptores y5 de neuropeptidos composiciones farmaceuticas que las contienen | |
| NI200300053A (es) | Derivados del tropano utiles en terapia. | |
| PE20060627A1 (es) | Derivados de pirazol condensado como agonistas de los receptores cannabinoides cb1 y/o cb2 | |
| PE20020761A1 (es) | Heteroarilo urea como antagonistas de los receptores y5 del neuropeptido y | |
| PE20081316A1 (es) | COMPUESTOS HETEROCICLICOS QUE MODULAN LA ACTIVIDAD DE LA ESTEROIL-CoA-DESATURASA | |
| EA200501504A1 (ru) | Лиганды каннабиноидных рецепторов и их применение | |
| AR056893A1 (es) | Compuestos heterociclicos fusionados y no fusionados, antagonistas de receptores mineralocorticoides | |
| PE20011030A1 (es) | Combinaciones farmaceuticas que comprenden tegaserod y omeprazol | |
| ATE459352T1 (de) | Benzimidazol-cannabinoid-agonisten mit einer substituierten heterocyclischen gruppe | |
| PE20090741A1 (es) | Derivados de 1,1,1-trifluor-2-hidroxi-3-fenilpropano | |
| PE20030603A1 (es) | Derivados de quinolina | |
| EA201000316A1 (ru) | Производные изохинолинила и изоиндолинила в качестве антагонистов гистаминовых рецепторов 3 подтипа | |
| ATE168102T1 (de) | 1,4-benzodiazepinderivate und ihre verwendung als cck-modulatoren | |
| PE20081152A1 (es) | Azaciclilaminas n-sustituidas como antagonistas de histamina-3 | |
| PE20060625A1 (es) | Derivados de benzazepina como antagonistas y/o agonistas del receptor h3 de histamina | |
| PE20071224A1 (es) | Derivados de aminometilpiridina como antagonistas de los receptores cannabinoides 1 (cb1) | |
| DK1189900T3 (da) | Heterocykliske aminopyrrolidinderivater som melatonerge lægemidler | |
| AR053307A1 (es) | Compuesto de anillos triciclicos fusionados,su uso para la fabricacion de un medicamento y composicion farmaceutica que lo comprende | |
| GT200300183A (es) | Nuevos agonistas ppar-alfa y ppar-gamma | |
| PE20001427A1 (es) | Compuestos de benzimidazol que son antagonistas del receptor de vitronectina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |